Skip to content

Improving Frailty in Patients With Stable Ischemic Heart Disease

Impact of a Program Aimed at Improving Frailty in Patients With Stable Ischemic Heart Disease in Primary Care: Fragicor Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07373119
Acronym
FRAGICOR
Enrollment
60
Registered
2026-01-28
Start date
2025-10-01
Completion date
2026-12-31
Last updated
2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

frailty, coronary heart disease, elderly

Brief summary

The goal of this clinical trial is to improve the frailty in old patients who have a cardiac disease . Researchers will determine the improvement in the instability and the strength along twelve sessions based on guided exercises and mobility techniques made by physiotherapists. Research team will also evaluate the medications and diet, as well as laboratory and clinical tests.

Detailed description

Intitial visit to measure quality of life, instability and strenght, followed by twelve sessions, one each week will be performed

Interventions

OTHERphysiotherapy

Primary care based physiotherapy groups

Sponsors

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

It is an experimental study before-after based on a program of 12 sessions of physiotherapy in primary care setting

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 70 years * Diagnosis of coronary artery disease (International Classification Diseases (ICD)-10 I20-I25) * Canadian Cardiovascular Society Class I * Low cardiovascular risk according to

Design outcomes

Primary

MeasureTime frameDescription
Short Physical Performance Battery (SPPB) components (balance, gait speed, chair rise)From enrollment to the end of treatment ending after 12 weeks.Improvement in baseline values: each of the three component scores \<= 4 points, and tests consists of: balance test, Gait speed and chair-stand tests. Maximum possible is 12 points and under 10 points means frailty

Secondary

MeasureTime frameDescription
Euroqol5D Goldberg Anxiety and Depression Scale Number of falls throughout the study Major Cardiovascular events Adherence to the programfrom the baseline to 12 weeks of interventionEuroqol5D measures the Quality of life through an Analogic Visual Scale, which ranks from 0 (worst) to100(best) Goldberg anxiety and depression scales measure the probabilty of suffering from anxiety or depression. The tests consist in a total of 9 questions for each dimension. A score of \>=4 in any of the dimensions suggest pathology. Adherence to the program will be evbaluated counting the attendance to the sessions. More than 9 sessions will be considerated good adherence

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026